[144] Taysha Gene Therapies, Inc. SEC Filing

Rhea-AI Filing Summary

Taysha Gene Therapies insider notice to sell 19,604 shares via Maxim Group under Rule 144. The filing reports a proposed sale of 19,604 shares of common stock with an aggregate market value of $56,263.48 based on the filer’s information. The shares represent vested RSU awards acquired and settled in stock on 08/21/2025; the stated consideration for those awards was the reporting person’s continued service as an employee. The filing lists total outstanding shares of 272,794,885 and identifies Nasdaq as the exchange for the approximate sale date of 08/21/2025. No other sales in the past three months were reported.

Positive

• Transaction disclosed under Rule 144, indicating compliance with resale reporting requirements
• Shares originated from vested RSU awards, and the filing states the consideration (continued service) clearly
• Broker identified (Maxim Group LLC), providing execution transparency

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine Form 144 disclosure of a small, post-vest insider sale; no material change to capitalization.

The filing documents a proposed sale of 19,604 shares, derived from vested RSUs settled in stock on 08/21/2025. At an aggregate market value of $56,263.48 against 272,794,885 shares outstanding, the transaction is immaterial to overall capitalization. The use of a broker (Maxim Group LLC) and the Rule 144 notice are consistent with standard compliance for restricted securities becoming eligible for public resale.

Corporate Governance Expert

TL;DR: Disclosure follows standard insider-selling procedures; no governance red flags visible from this notice.

The form states the shares were awarded as RSUs and settled upon vesting with consideration being continued employment, and the filer affirms lack of undisclosed material information. The filing includes broker details and sale timing under Rule 144, matching expected governance and disclosure practices for an employee post-vesting sale.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Maxim Group LLC 300 Park Avenue, 16th Floor New York NY 10022	19604	56263.48	272794885	08/21/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	08/21/2025	RSU Award	Issuer			19604	08/21/2025	Vested grant settled instock; consideration was Reporting Person's continued service as an employee ofthe Issuer.

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did the TSHA Form 144 disclose about the insider sale?

The filing discloses a proposed sale of 19,604 common shares with an aggregate market value of $56,263.48, to be executed approximately on 08/21/2025 via Maxim Group LLC on Nasdaq.

What is the origin of the shares being sold in the TSHA Form 144?

The shares were acquired as a vested RSU award settled in stock on 08/21/2025; the stated consideration was the reporting person’s continued employment.

How large is the proposed sale relative to TSHA's outstanding shares?

The filing reports 272,794,885 shares outstanding; the proposed sale of 19,604 shares is immaterial relative to that total.

Were any other securities of TSHA sold by the reporting person in the past three months?

The filing states Nothing to Report for securities sold during the past three months.

Does the Form 144 indicate any undisclosed material information about TSHA?

By signing, the reporting person represents they do not know any material adverse information about the issuer that has not been publicly disclosed.